Skip to Content

Lixte Biotech Holdings Inc - Stock Quote LIXT

Rating as of

Morningstar's Lixte Biotech Holdings Inc Stock Analysis

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Lixte Biotech Holdings Inc's Company Profile

Business Description

Lixte Biotech Holdings Inc is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. The company focuses on developing new treatments for human cancers for which therapies are urgently needed. It mainly designs drugs for which there are existing data suggesting any effect on altered pathways of the cancer cell and may be given safely to humans. The development program of the company includes drugs for the treatment of cancer, consisting of protein phosphatase inhibitors and histone deacetylase inhibitors.

680 East Colorado Boulevard, Suite 180
Pasadena, CA, 91101
T +1 631 830-7092
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Mar 31, 2022
Fiscal Year End Dec 31, 2022
Stock Type Distressed
Employees 4